Due to advances in obstetric and transplant medicine, women with a history of liver transplantation can have successful pregnancies. However, data on pregnancy outcomes is still limited, especially for women who have had a repeat liver transplant following graft rejection. This retrospective study compares pregnancy outcomes in women with single and repeat liver transplants managed at 2 tertiary hospitals in Toronto, Canada and Leuven, Belgium. We identified 41 pregnancies in 28 transplanted women, 6 of whom conceived following a second liver transplant after the first was rejected. Mean maternal age at delivery was 30 6 7 years, and transplant-to-pregnancy interval was 8.5 6 5.1 years. All women had normal liver function upon conception. Immunosuppressants included tacrolimus 6 azathioprine (n 5 26), cyclosporine (n 5 4), and prednisone with immunosuppressants (n 5 11). There were no maternal deaths. Maternal complications included hypertensive disorders of pregnancy (n 5 10), deterioration in renal function (n 5 6), gestational diabetes (n 5 4), graft deterioration (n 5 2), and anemia requiring blood transfusion (n 5 1). Fetal/neonatal adverse outcomes included 2 miscarriages, 3 stillbirths, 1 neonatal death, 5 small-for-gestational-age infants, and 1 minor congenital anomaly. Mean gestational age at delivery was 36.7 6 4.2 weeks. There were 14 (38.9%) preterm births. Outcomes in women with a second transplant were similar to those with a single transplant, except for a higher incidence of hypertensive disorders. In conclusion, with appropriate multidisciplinary care, stable graft function at pregnancy onset, and adherence to immunosuppressive regimens, women with single and repeat liver transplants have low rates of graft complications but remain at increased risk for pregnancy complications. Immunosuppressants and high-dose glucocorticoids can be safely used for maintenance of graft function and management of graft deterioration in pregnancy.
The number of successful liver transplantations is increasing worldwide. Transplant statistics as regularly reported from the United States suggest that the number of adult liver transplant recipients alive in 2012 (56,900) was almost exactly twice the number alive in 2002. (1) As 40% of all liver transplant recipients are women, transplant physicians, family doctors, and obstetricians increasingly encounter pregnancies in transplant recipients. A recent systematic review described outcomes of 450 pregnancies in 306 liver transplant recipients (2) and showed that although pregnancy complications such as miscarriages, preterm birth, preeclampsia, and cesarean deliveries were lower than with renal transplants, they were still significantly higher than the general population. As experience with the management of pregnancies in women following liver transplantation around the world continues to grow, it is hoped that pregnancy outcomes will continue to improve. In addition, there is very little published data on outcomes of pregnancies after repeat liver transplantation for previous transplant rejection. The aim of our study is to describe the experience of 2 large referral centers with the management of pregnancies following single and repeat liver transplantation and to compare outcomes between these 2 groups of women.
Patients and Methods
We retrospectively identified all women who had a pregnancy following liver transplantation and attended the antenatal obstetric clinics at Mount Sinai Hospital, Toronto, Canada and the University Hospital Leuven, Leuven, Belgium between 1989 and 2016. After receiving research ethics board (REB) approval at both the sites (14-0339-C in Toronto and REB-30-Nov-15 in Leuven), we reviewed medical records and extracted data on maternal demographics, details on the liver transplantation and graft health, immunosuppressive therapy and liver function at the onset of pregnancy, comorbidities, pregnancy-related outcomes such as mode of conception and number of fetuses, maternal complications such as maternal death, graft rejection or failure, deterioration of liver function, gestational diabetes mellitus, hypertensive disorders of pregnancy (3) including preeclampsia (elevated blood pressure after 20 weeks of gestation with proteinuria or in the absence of proteinuria but with the association of thrombocytopenia, impaired liver function, newonset renal insufficiency, pulmonary edema or newonset cerebral or visual symptoms); gestational hypertension (elevated blood pressure after 20 weeks of gestation in the absence of proteinuria or other systemic findings); and chronic hypertension with superimposed preeclampsia. We also recorded fetal/neonatal outcomes including fetal loss (defined as miscarriage if the loss was <20 weeks and a stillbirth if >20 weeks), mode of delivery, small for gestational age (defined as birth weight under the tenth percentile for gestational age and sex), (4) preterm birth if delivered under 37 weeks of gestation, neonatal Apgar scores at 5 minutes, presence of congenital malformations, and admission to the neonatal intensive care unit (NICU). Where possible, we obtained results from placental histopathology and classified them based on the Amsterdam Placental Workshop Group Consensus Statement. (5) We also obtained data on longterm follow-up of both mother and infant when possible.
Results were presented as means and standard deviations, ranges, and proportions. We also compared outcomes of pregnancies after a single transplant with those in women who underwent repeat liver transplantation for graft loss using the chi-squared test for categorical variables and the Mann-Whitney U test for continuous variables, and the outcomes of our study with those published in a recent systematic review on the topic. (2) A P value of 0.05 was considered significant.
Results

MATERNAL CHARACTERISTICS
We identified 28 women who had 41 pregnancies following liver transplantation between 1989 and 2016. The characteristics of these pregnancies as well as the indications for transplantation and immunosuppressants used at the time of conception are described in Table 1 . The mean maternal age at delivery was 30 6 7 years, and the mean transplant-to-pregnancy interval was 8.5 (6 5.1) years. Eight pregnancies were conceived following assisted reproductive techniques. There were 4 dichorionic diamniotic twin pregnancies. A total of 6 women had 10 pregnancies after a second transplant, the details of which are presented in Fig. 1 . Immunosuppressive treatment is outlined in Table 1 . A total of 20 women (71.4%) had other significant comorbidities predating pregnancy. These included chronic kidney disease (n 5 5) of which 2 were on dialysis, chronic hypertension (n 5 4), depression (n 5 3), thrombocytopaenia (n 5 3), splenectomies (n 5 2), a prior nonhematologic solid organ malignancy (n 5 1), renal transplant (n 5 1), hypothyroidism and tuberculosis (n 5 1), cervical tuberculous lymphadenopathy, mitral regurgitation and thrombotic thrombocytopenic purpura (n 5 1).
There were 6 women who had repeat liver transplantations for graft rejection (n 5 4), portal vein thrombosis (n 5 1), and biliary stricture (n 5 1). These women had 10 pregnancies that resulted in 6 term live births, 3 preterm live births, and 1 stillbirth. Their medical and obstetric history is summarized schematically in Fig. 1 , and pregnancy outcomes compared with single transplant recipients are listed in Table 2 . The only difference in outcomes between women with single and repeat liver transplants was in the rates of hypertensive disorders of pregnancy (5/31 versus 5/10, P 5 0.03).
PREGNANCY OUTCOMES
There were no maternal deaths. Two women had deterioration of graft function, the details of which are presented in Fig. 2 . The first patient conceived 5 years after her second transplant, the initial transplant being for fulminant hepatic failure of unknown cause. She was on cyclosporine and prednisone for maintenance immunosuppression at the time of conception. At 33 weeks of gestation, her liver enzymes were found to be elevated on routine testing. A liver biopsy was inconclusive. The patient was started on intravenous steroids for a presumed diagnosis of graft rejection. The liver enzymes continued to increase. A second biopsy showed microvesicular fatty infiltration with no signs of rejection. A diagnosis of acute fatty liver of pregnancy was made after excluding other causes of fatty liver, and the patient was delivered at 3316 weeks. Liver function normalized after delivery. The second patient conceived 5 years after transplantation for alpha 1 antitrypsin deficiency. Following her transplant, she developed a lymphoproliferative disorder requiring chemotherapy, and later on developed hypertension and chronic renal failure. She was originally on tacrolimus 5 mg bid (twice a day), which was at some point reduced to 1 mg bid, presumably as a result of renal dysfunction. When she was seen by the transplant team early in her pregnancy, her dose of tacrolimus was changed back to 5 mg bid. At 31 weeks, her blood pressure was elevated and her blood work showed rising creatinine levels (109 to 223 micromol/ L), mild elevation of liver enzymes (AST and ALT from 49/59 units/L to 61/68 units/L), and elevated uric acid (590 micromol/L) and was initially diagnosed as a case of graft deterioration, although in retrospect, this might have been a result of tacrolimus-induced nephrotoxicity (tacrolimus levels 12.1ng/ml, therapeutic range 5-10 ng/ml). However, an unexplained stillbirth ensued at 3113 weeks. The final diagnosis remained in question; however, the sequence of events did not suggest graft rejection but instead prepregnancy renal impairment with superimposed preeclampsia and tacrolimus nephrotoxicity. The reason for fetal demise also remained undetermined. There was no suggestion of placental insufficiency on placental histopathology, the only findings being fibromuscular sclerosis and karyorrhexis consistent with stillbirth, in a placenta on the eighty-fifth percentile for gestational age. Whether tacrolimus played a role in the fetal demise could not be determined. Liver enzymes returned to normal within 3 days of delivery. She went on to have another pregnancy just over 1 year later and delivered a healthy preterm infant at 3315 weeks. Incidentally, her liver enzymes transiently increased during the second pregnancy as well.
One patient conceived within a year of transplantation and another conceived just under 2 years following transplantation. Neither of these suffered deterioration of graft function or other pregnancy complications.
A total of 10 pregnancies (2 of which included multiple gestations) were affected by hypertensive disorders. Of these, 5 pregnancies occurred in 3 women with repeat liver transplants. These women had no history of chronic hypertension, although 1 was on longterm nocturnal dialysis for posttransplant acute renal failure. The other 5 cases of hypertension occurred in women with a single transplant, all 5 of whom had preexisting hypertension and/or chronic renal insufficiency and went on to develop preeclampsia in the third trimester resulting in 4 preterm (between 29 and 33 weeks) and 1 term delivery. New-onset maternal renal insufficiency was seen in 1 patient who had received 2 liver transplants 12 years apart and had multiple comorbidities as described in Fig. 1 (case 4) . Four patients developed gestational diabetes, of whom 2 were on glucocorticoids and 1 patient with a twin pregnancy developed anemia in pregnancy requiring a blood transfusion.
There was 1 first trimester miscarriage and 1 second trimester (16 weeks) miscarriage. The latter patient was on daily nocturnal hemodialysis for chronic renal failure. She had a successful term pregnancy prior to the miscarriage but had another stillbirth at 22 weeks gestation in a subsequent pregnancy. There were 2 other stillbirths at 21 and 3113 weeks respectively, 1 associated with preeclampsia, and the other with transient elevation in liver enzymes and possible preeclampsia and tacrolimus-induced nephrotoxicity as discussed earlier, but no overt signs of graft rejection.
Of the 36 remaining pregnancies, 14 (38.9%) delivered preterm, the range being between 2310 and 3615 weeks of gestation (Supporting Table S1 ). Of these, only 3 presented in spontaneous labor, while 11 (78.6%) were induced or delivered by elective cesarean on account of hypertensive disorders of pregnancy including preeclampsia and HELLP syndrome (n 5 7), fetal wellbeing concerns or growth restriction (n 5 2), suspected acute fatty liver of pregnancy (n 5 1), and deterioration of maternal renal function and thrombocytopenia in a patient already in chronic renal failure (n 5 1). Despite the high number of preterm births, the mean gestational age at delivery was 36.7 6 4.2. Among the 22 patients who delivered at term, labor was induced in 13 (59.1%) for reasons that included postdated pregnancies (n 5 3), diabetes (n 5 3), suspected fetal compromise (n 5 3), preeclampsia (n 5 2), graft deterioration (n 5 1), and worsening renal insufficiency (n 5 1). With regard to the final mode of delivery, 19 (52.7%) delivered vaginally and 11 had cesarean deliveries in labor. All 6 elective cesarean deliveries were for obstetric indications.
NEONATAL OUTCOMES
There were no congenital malformations apart from 1 infant with a small ventricular septal defect. Four infants needed admission to the NICU on account of prematurity. The only neonatal death was a consequence of extreme prematurity in a fetus delivered at 23 weeks. Mean birthweight was 2587 6 909.3 g (range 660 g-4220 g). One neonate (2.8%) had a birth weight below the tenth percentile for gestation.
LONGTERM MATERNAL OUTCOMES
Maternal follow-up at a median of 7.2 years (range 2.2-14.1 years) showed no cases of transplant loss. One woman with a history of ulcerative colitis developed colorectal cancer 5 1/2 years after delivery. No other maternal complications were noted on longterm follow-up. The 6 women with histories of 2 liver transplants had 10 pregnancies following the second transplant that resulted in 9 live births and 1 stillbirth at 21 weeks.
Placental Histopathology
Placental histopathology was only available in 9 cases, all features of which were in keeping with the obstetrical presentation (Supporting Table S2 ). The main findings included features of maternal and fetal vascular malperfusion, delayed villous maturation, infection, and chronic inflammation. Although these findings are clinically significant, they were in keeping with the obstetrical presentation and not related to liver function or to administration of immunosuppressive agents.
Discussion
This retrospective 2-center study describing 41 pregnancies in 28 transplant recipients and comparing pregnancy outcomes in women with single and repeat liver transplants showed that pregnancy outcomes following liver transplantation are reassuring in general and that those with repeat transplants have comparable outcomes except for an increase in hypertensive disorders of pregnancy, even in the absence of chronic hypertension.
Although women with a history of liver transplantation can have successful pregnancies and pregnancy outcomes continue to improve, these patients are still at risk for adverse maternal and perinatal outcomes
and require prepregnancy counseling and management by a multidisciplinary team comprising maternalfetal medicine physicians, transplant specialists, hepatologists, obstetric medicine physicians, anaesthesiologists, neonatologists, and specialist nurses/midwives. Our study findings compare favorably with those of a recent systematic review (Table 3 ), yet our cohort had a higher risk of stillbirths (3/41 versus 4/450, P <0.01), all of which were secondary to chronic renal dysfunction and maternal hypertension. As graft rejection and deterioration are more common in the first year after transplantation, the National Transplant Pregnancy Registry, the American Association for the Study of Liver Diseases, and the American Society of Transplantation recommend delaying conception at least a year following transplantation, (6, 7) while European guidelines (8) and other authors recommend a delay of at least 2 years to ensure stable allograft function and excellent maternal and neonatal outcome. (9) In our study, the patient who conceived within a year was on cyclosporine and steroids and had abnormal liver enzymes throughout pregnancy. The patient who conceived just under 2 years following transplantation was on tacrolimus, prednisone, and insulin for gestational diabetes. Both had uncomplicated deliveries at term.
Although maternal mortality (9) (10) (11) and graft rejections (10.5-21%) (10) (11) (12) (13) (14) (15) during pregnancy have been reported in the literature, we did not encounter these complications in our cohort. Despite good compliance with maintenance immunosuppressive therapy, however, 2 patients experienced deterioration of graft function.
Chronic kidney disease and hypertension are common in patients with liver transplantation, and this could be due to a number of reasons including the use of calcineurin inhibitors, perioperative acute kidney injury, autoimmune conditions, infections, and diabetes. In our cohort, 18% had chronic renal failure and 14% had hypertension prior to conception. These are risk factors for development of preeclampsia that affected 10 (24.4%) of our cohort, similar to that reported in a recent systematic review. (2) Similarly, the rate of gestational diabetes in our study (9.8%) was no higher than in other studies.
Although the live birth rate in our cohort was high at 87.8%, our stillbirth rate was significantly higher than that in the reported literature (3/41 versus 4/450, P 5 0.02). There could be a number of reasons for this. There is no globally accepted definition for stillbirth, and various geographical regions use thresholds ranging from 20 weeks to 28 weeks. (16) The smaller numbers seen in the systematic review could be a result of definitions different from ours. It is worth noting that 2 of our stillbirths occurred before 24 weeks of gestation, which in many countries, including the United Kingdom would have been reported as miscarriages rather than stillbirths. The 1 stillbirth that occurred at 3113 weeks was due to an undetermined cause. The lack of placental findings on histopathology suggests that placental insufficiency might not have been a cause. One theory is that this could have been drug-induced from tacrolimus toxicity. Although stillbirths from tacrolimus toxicity have not been described, there are reports of neonatal hyperkalemia and renal failure secondary to tacrolimus toxicity. (17) Almost 40% of these fetuses were delivered preterm. This is in keeping with the high preterm birth rates reported in the literature. (2, 18, 19) Similar to that reported in the literature, most of these preterm births (9/14) occurred after 3210 weeks of gestation, and the average gestational age was 36.7 6 4.2 weeks. (2) These preterm births were mostly induced on account of maternal and obstetric reasons, including preeclampsia and fetal well-being concerns. Only 3 patients presented with spontaneous preterm labor, none of which could be directly attributed to graft function. Other adverse perinatal outcomes that included 1 minor congenital anomaly, 1 (2.8%) small for gestational age fetuses, and 1 neonatal death due to extreme prematurity were no different from published findings. All cesarean deliveries were for obstetric indications, and the high rate (47%) seen in our cohort is also comparable with the systematic review (44.6%). (2) The main limitations of our study are small numbers that did not allow a suitable regression analysis, the retrospective study design, and limited longterm follow-up. However, our study is the first to report pregnancy outcomes following liver transplantation in Canadian and Belgium liver transplant populations, and although other studies have reported pregnancy outcomes in women with repeat transplants, (11, 20) the first to compare outcomes between women with single and repeat transplants. Pregnancy outcomes are reassuringly comparable with other international centers. Although complications such as graft deterioration, stillbirths, prematurity, and growth restriction are still commonly encountered, with multidisciplinary care and current immunosuppressive regimens, women with liver transplants can expect successful pregnancies with no increase in congenital malformations or neonatal complications.
Although making specific clinical recommendations is beyond the scope of this retrospective study, we have found that adhering to a few general principles could improve pregnancy outcomes. Preconception counseling by specialists in maternal-fetal medicine and transplant medicine is vital for optimizing immunosuppressant regimens and ensuring adequate graft function prior to embarking on a pregnancy. Decisions on whether pregnancies should be deferred for 1 year (6, 7) or 2 years (8, 9) following stable graft function should take into account factors such as maternal age, which could influence pregnancy outcomes. During pregnancy, liver function tests (and immunosuppressant levels if indicated) should be performed monthly and if stable, we recommend routine antenatal care, which in our practice involves monthly visits until 28 weeks of gestation, biweekly between 28 and 36 weeks of gestation, and weekly visits thereafter until delivery. We also recommend fetal growth surveillance through obstetric ultrasound, once a month in the third trimester. Given the increased risk of pregnancy complications in this population, decisions on titrating the dose of immunosuppressive medications, management of antenatal complications, and decisions regarding timing and mode of delivery are best made by maternal-fetal medicine physicians in conjunction with transplant physicians.
